Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
MAZE
Strong SellSinkerMaze Therapeutics, Inc. · Healthcare · United States · $1.5B · Avg Vol: $10M/d
COMPANY DESCRIPTION
Maze Therapeutics, Inc. is a clinical-stage biopharmaceutical company leveraging its proprietary "human genetic discovery engine" to identify and validate novel drug targets for common diseases. By integrating human genetics and functional genomics, the company aims to develop precision medicines that modulate disease-modifying genes. Its competitive advantage lies in its unique platform for identifying genetically-driven therapeutic opportunities and its focus on developing highly targeted treatments for underserved patient populations.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 167.5M | 0 | — | — | 20.0M | 8.8M | -62.5% |
| EPS | -3.29 | -2.87 | 0.08 | -3.05 | — | -2.44 | -2.73 | -3.18 | — |
| Shares | 43.8M | 43.8M | 43.8M | 49.3M | +12.7% | 55.5M | — | — | — |
| Debt | 32.1M | 49.6M | 26.6M | 23.3M | -10.1% | 60.4M | — | — | — |
| Equity | -282.5M | -373.8M | -311.2M | 355.0M | — | — | — | — | — |
| Op CF | -99.2M | -86.8M | 76.0M | -111.9M | — | -106.5M | — | — | — |
| Inv CF | -3.2M | -0.4M | -1.1M | -171.0M | — | — | — | — | — |
| Fin CF | 1.7M | 16.4M | 92.8M | 275.3M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of MAZE are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| MAZE | Maze Therapeutics, Inc.(you) | $1.5B | 8 | Strong Sell |
| TYRA | Tyra Biosciences, Inc. | $1.5B | 8 | Strong Sell |
| LTGO | Latigo Biotherapeutics, Inc. | $1.5B | 8 | Strong Sell |
| TRAX | First Tracks Biotherapeutics, Inc. | $1.5B | 6 | Strong Sell |
| AVLN | Avalyn Pharma Inc. | $1.5B | 10 | Strong Sell |
| SNDX | Syndax Pharmaceuticals, Inc. | $1.7B | 6 | Strong Sell |
| NTLA | Intellia Therapeutics, Inc. | $1.8B | 7 | Strong Sell |
| AKTS | Aktis Oncology, Inc. | $1.4B | 11 | Strong Sell |
| SPTX | Seaport Therapeutics, Inc. | $1.3B | 10 | Strong Sell |
| CRVS | Corvus Pharmaceuticals, Inc. | $1.2B | 8 | Strong Sell |
Peer medians: ROE -30.2% · P/E 27.0x · Gross margin 58.1%